Skip to main content
. 2013 Sep 4;14(12):1098–1103. doi: 10.4161/cbt.26343

Table 3. Response to cetuximab-based regimens and to single agent panitumumab (N = 30).

Response Cetuximab-based regimens Single agent panitumumab
  No % No %
Complete response (CR) 1 3 0 0
Partial response (PR) 17 57 9 30
Stable disease (SD) 12 40 11 37
Progressive disease (PD) 0 0 10 33
Disease control rate (CR + PR + SD)   100 20 67